Management of Vaginal Dryness and Discomfort

First-Line Treatments

The American College of Obstetricians and Gynecologists recommends starting with over-the-counter water-based or silicone-based lubricants for sexual activity and vaginal moisturizers applied 3-5 times weekly; if symptoms persist after 4-6 weeks, escalate to low-dose vaginal estrogen products 1
Silicone-based lubricants may last longer than water-based products and are effective alternatives 1
Vaginal moisturizers should be applied 3-5 times per week to the vagina, vaginal opening, and external vulva for optimal symptom control 1
Replens is a non-hormonal moisturizer that showed transient improvement in vaginal symptoms in breast cancer survivors 2, 3

Low-dose vaginal estrogen products, including Premarin cream, estradiol tablets, and estradiol rings, are recommended for moderate to severe vaginal dryness, itching, and burning in postmenopausal women 1
Estradiol cream 0.003% applied daily for 2 weeks, then twice weekly for maintenance, is an effective treatment option 1
Estriol-containing preparations may be preferable for women on aromatase inhibitors, as estriol is a weaker estrogen that cannot be converted to estradiol 2, 1

Intravaginal DHEA (prasterone) is FDA-approved for vaginal dryness and pain with sexual activity in postmenopausal women, improving sexual desire, arousal, pain, and overall sexual function 2, 1
Intravaginal testosterone cream has been shown safe and effective in postmenopausal breast cancer survivors on aromatase inhibitors 2, 1
Ospemifene (oral SERM) is FDA-approved for moderate to severe dyspareunia in postmenopausal women without breast cancer history 1

For women with breast cancer history, try non-hormonal options first at higher frequency; if vaginal estrogen is needed, discuss risks and benefits thoroughly, and consider estriol-containing preparations over estradiol 2, 1
A large cohort study of nearly 50,000 breast cancer patients showed no increased risk of breast cancer-specific mortality with vaginal estrogen use over 20 years of follow-up 1
Small retrospective studies suggest vaginal estrogens do not adversely affect breast cancer outcomes 2, 1